Latest Breaking News On - Ajayk nooka - Page 1 : vimarsana.com

Elranatamab Represents Another Off-the-Shelf Option for Heavily Pretreated R/R Myeloma

Ajay Kumar Nooka, MD, MPH, FACP, highlights the significance of the FDA approval of elranatamab for select patients with relapsed/refractory multiple myeloma and expands the agent’s role in the expanding field of T cell–redirecting therapies approved for the treatment this patient population.

Emory universityUnited statesAjay kumar nookaOncology at emory university school of medicineDepartment of hematologyMyeloma programMedical oncologyEmory university schoolWinship dataTechnology applications shared resourceWinship cancer instituteMultiple myelomaBcma directed therapyAntibody drug conjugateCart cell therapyCar t

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

Dr Nooka discusses the FDA approval of elranatamab in relapsed/refractory multiple myeloma, key data from MagnetisMM-3, and the evolving role of bispecific antibodies in the multiple myeloma treatment paradigm.

Emory universityUnited statesAshling wahnerAjayk nookaMyeloma programOncology at emory university school of medicineDepartment of hematologyMedical oncologyEmory university schoolWinship dataTechnology applications shared resourceWinship cancer instituteApple podcastsGoogle podcastsAmazon musicFda approval of elranatamab

IMF Medical Student Scholars for Health Equity in Myeloma Present Research at the 2023 NMA Annual Convention & Scientific Assembly

IMF Medical Student Scholars for Health Equity in Myeloma Present Research at the 2023 NMA Annual Convention & Scientific Assembly
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUniversity of chicagoMemorial sloan kettering cancer centerCollege parkManisha bhutaniTafadzwa amaniYelak biruMo racquel innis sheltonJustin thomasSemaj testamarkPa saad usmaniJeffrey zonderMonica bertagnoliAjayk nookaRandallc morgan jr

Elranatamab Elicits Responses in Pretreated Relapsed/Refractory Myeloma

Elranatamab led to early and deep responses in patients with relapsed/refractory myeloma who were previously treated with a BCMA-directed therapy.

Ajayk nookaEastern cooperative oncology groupMyeloma international staging systemEmory university school of medicineEmory university schoolWinship dataTechnology applications shared resourceWinship cancer instituteEmory universityAsco annual meeting

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.

United statesEmory universityTocilizumab actemraAjayk nookaSecura bioBristol myers squibb celgeneMyeloma international staging systemMyeloma programBristol myers squibbBeyondspring pharmaceuticalsDepartment of hematologyInternational myeloma working groupOncology at emory university school of medicineMedical oncologyEmory university schoolWinship data